Dr. Jingjing C. Hu

Hematology
Office
101 Columbian St Fl 2, 
South Weymouth, MA 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Office
101 Columbian St Fl 2, 
South Weymouth, MA 

Overview

Jingjing Hu is a Hematologist practicing medicine in South Weymouth, Massachusetts.

Her clinical expertise encompasses Gastroesophageal Junction Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and ALK-Positive Non-Small Cell Lung Cancer.

She is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 4 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NH

Hospital Affiliations

Southern Nh Medical Center
Elliot Hospital
Wentworth-Douglass Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Office
101 Columbian St Fl 2, South Weymouth, MA 02190
Other Locations
Nashua Oncology & Hematology
10 Prospect St Ste 202, Nashua, NH 03060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: Trastuzumab-Emtansine, Trastuzumab SC, Paclitaxel
Study Phase: Phase 2
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Enrollment Status: Recruiting
Publish Date: April 29, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab Govitecan, Pembrolizumab
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Sacituzumab Govitecan
Study Phase: Phase 2
View 2 Less Clinical Trial

40 Total Publications

Rising Incidence With Modest Survival Improvement in Salivary Duct Carcinoma: A Population-Based Study in the United States, 2000-2022.
Rising Incidence With Modest Survival Improvement in Salivary Duct Carcinoma: A Population-Based Study in the United States, 2000-2022.
Journal: Head & neck
Published: April 16, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (14.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (14.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Tufts Medical Center Hematology

860 Washington St Bldg 7, 
Boston, MA 
 (13.8 miles away)
617-263-8312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Comenzo is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Comenzo is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Multiple Myeloma, Cardiac Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Comenzo is currently accepting new patients.

Frequently Asked Questions about Dr. Jingjing C. Hu

How do I make an appointment with Dr. Jingjing C. Hu?

You can book an appointment with Dr. Jingjing C. Hu by calling their office at 781-624-4800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jingjing C. Hu a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jingjing C. Hu is classified as an Experienced expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jingjing C. Hu specialize in?

While Dr. Jingjing C. Hu is a Hematology, they have specific expertise in Gastroesophageal Junction Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jingjing C. Hu participate in research or clinical trials?

Yes. Dr. Jingjing C. Hu has published 40 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Dr. Jingjing C. Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jingjing C. Hu accept my insurance?

Dr. Jingjing C. Hu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 781-624-4800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
        View All 39 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile